RNA Virus Infections
41
1
1
31
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.3%
3 terminated out of 41 trials
91.2%
+4.7% vs benchmark
20%
8 trials in Phase 3/4
32%
10 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (41)
Therapeutics for Moderate and Severe Dengue
Effectiveness of Ammonium Chloride in Reducing Viral Load
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
Clinic-based ART Diagnostic Evaluation
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19
EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)